Clinical Trials
11
Active:0
Completed:10
Trial Phases
2 Phases
Phase 1:1
Phase 2:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
10 (90.9%)Phase 1
1 (9.1%)A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
Phase 2
Recruiting
- Conditions
- Dercum's Disease
- Interventions
- Drug: CBL-514 injection
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06303570
- Locations
- 🇺🇸
Investigator Site, Spokane, Washington, United States
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
Phase 2
Completed
- Conditions
- Subcutaneous Fat
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 173
- Registration Number
- NCT06005441
- Locations
- 🇺🇸
Investigational Site 1, Omaha, Nebraska, United States
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
Phase 2
Completed
- Conditions
- Cellulite
- Interventions
- Drug: CBL-514 injection
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05836779
- Locations
- 🇺🇸
Investigational Site 6, Encinitas, California, United States
🇺🇸Investigational Site 1, Encino, California, United States
🇺🇸Investigational Site 3, San Diego, California, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Phase 2
Completed
- Conditions
- Subcutaneous Fat
- Interventions
- Drug: CBL-514 InjectionOther: 0.9% Sodium Chloride
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT05736107
- Locations
- 🇺🇸
Investigational site 1, Pflugerville, Texas, United States
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)
Phase 2
Completed
- Conditions
- Cellulite
- Interventions
- Drug: 40 mg CBL-514Drug: 60 mg CBL-514Drug: 80 mg CBL-514
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05632926
- Locations
- 🇺🇸
Investigational Site 1, Encino, California, United States
🇺🇸Investigational Site 2, New York, New York, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found